1. Home
  2. ETWO vs NTLA Comparison

ETWO vs NTLA Comparison

Compare ETWO & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETWO
  • NTLA
  • Stock Information
  • Founded
  • ETWO 2000
  • NTLA 2014
  • Country
  • ETWO United States
  • NTLA United States
  • Employees
  • ETWO N/A
  • NTLA N/A
  • Industry
  • ETWO EDP Services
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • ETWO Technology
  • NTLA Health Care
  • Exchange
  • ETWO Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • ETWO 663.4M
  • NTLA 794.5M
  • IPO Year
  • ETWO N/A
  • NTLA 2016
  • Fundamental
  • Price
  • ETWO $3.28
  • NTLA $11.89
  • Analyst Decision
  • ETWO Sell
  • NTLA Buy
  • Analyst Count
  • ETWO 4
  • NTLA 19
  • Target Price
  • ETWO $2.78
  • NTLA $35.11
  • AVG Volume (30 Days)
  • ETWO 3.2M
  • NTLA 4.2M
  • Earning Date
  • ETWO 07-10-2025
  • NTLA 08-07-2025
  • Dividend Yield
  • ETWO N/A
  • NTLA N/A
  • EPS Growth
  • ETWO N/A
  • NTLA N/A
  • EPS
  • ETWO N/A
  • NTLA N/A
  • Revenue
  • ETWO $609,135,000.00
  • NTLA $45,569,000.00
  • Revenue This Year
  • ETWO $1.84
  • NTLA N/A
  • Revenue Next Year
  • ETWO $2.32
  • NTLA N/A
  • P/E Ratio
  • ETWO N/A
  • NTLA N/A
  • Revenue Growth
  • ETWO N/A
  • NTLA N/A
  • 52 Week Low
  • ETWO $1.75
  • NTLA $5.90
  • 52 Week High
  • ETWO $4.82
  • NTLA $27.77
  • Technical
  • Relative Strength Index (RSI)
  • ETWO 67.25
  • NTLA 67.14
  • Support Level
  • ETWO $3.21
  • NTLA $11.31
  • Resistance Level
  • ETWO $3.24
  • NTLA $12.34
  • Average True Range (ATR)
  • ETWO 0.01
  • NTLA 0.76
  • MACD
  • ETWO -0.02
  • NTLA 0.09
  • Stochastic Oscillator
  • ETWO 87.50
  • NTLA 91.88

About ETWO E2open Parent Holdings Inc.Class A

E2open Parent Holdings Inc is an end-to-end and cloud-based supply chain management SaaS platform. The company's software combines networks, data, and applications to provide a deeply embedded, mission-critical platform that allows customers to optimize the supply chain across channel shaping, business planning, logistics, trade, manufacturing, and supply management. The Group has one reportable segment consisting of cloud-based, end-to-end SCM software. Geographically, the company operates in the Americas, Europe, and Asia Pacific, out of which the majority is from the Americas.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: